Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASN-1324
- Development stage
- Unknown
- Lead developer
- Asana BioSciences
- Modality
- Small Molecules
- Administration
- Topical, Oral
01
Overview
ASN-1324 is a potent and selective small molecule inhibitor of the voltage-gated sodium channel Nav1.7 (encoded by the SCN9A gene), developed by Asana BioSciences. Nav1.7 is highly expressed in peripheral sensory neurons and plays a critical role in the transmission of pain and itch signals. By selectively blocking Nav1.7, ASN-1324 aims to provide therapeutic relief for conditions such as chronic pain and pruritus (itch) without the central nervous system side effects associated with non-selective sodium channel blockers or opioids. The compound has demonstrated efficacy in preclinical models of inflammatory and neuropathic pain, and its development has progressed under the clinical designation ASN008, particularly for dermatological pruritus.
Beyond the preview
Go deeper on ASN-1324.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASN-1324.